このエントリーをはてなブックマークに追加
ID 61458
フルテキストURL
fulltext.pdf 3.38 MB
著者
Ikeda, Tomoka Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Gion, Yuka Division of Pathophysiology, Okayama University Graduate School of Health Sciences Kaken ID researchmap
Nishimura, Yoshito Department of General Medicine, Okayama University Hospital ORCID publons researchmap
Nishimura, Midori Filiz Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yoshino, Tadashi Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kaken ID publons researchmap
Sato, Yasuharu Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences ORCID Kaken ID researchmap
抄録
Epstein-Barr virus (EBV)-positive mucocutaneous ulcer (EBVMCU) was first described as a lymphoproliferative disorder in 2010. EBVMCU is a unifocal mucosal or cutaneous ulcer that often occurs after local trauma in patients with immunosuppression; the patients generally have a good prognosis. It is histologically characterized by proliferating EBV-positive atypical B cells accompanied by ulcers. On the basis of conventional pathologic criteria, EBVMCU may be misdiagnosed as EBV-positive diffuse large B-cell lymphoma or other lymphomas. However, its prognosis differs from that of EBV-associated lymphomas, in that patients with EBVMCU frequently show spontaneous regression or complete remission without chemotherapy. Therefore, EBVMCU is now recognized as a low-grade malignancy or a pseudo-malignant lesion. Avoiding unnecessary chemotherapy by distinguishing EBVMCU from other EBV-associated lymphomas will reduce the burden and unnecessary harm on patients. On the basis of these facts, EBVMCU was first described as a new clinicopathological entity by the World Health Organization in 2017. In this review, we discuss the clinicopathological characteristics of previously reported EBVMCU cases, while focusing on up-to-date clinical, pathological, and genetic aspects.
キーワード
EBV-positive mucocutaneous ulcer
clinical features
pathological features
immunosuppression
発行日
2021-01-21
出版物タイトル
International Journal of Molecular Sciences
22巻
3号
出版者
MDPI
開始ページ
1053
ISSN
1422-0067
NCID
AA12038549
資料タイプ
学術雑誌論文
言語
English
OAI-PMH Set
岡山大学
著作権者
© 2021 by the authors.
論文のバージョン
publisher
PubMed ID
DOI
Web of Science KeyUT
関連URL
isVersionOf https://doi.org/10.3390/ijms22031053
ライセンス
http://creativecommons.org/licenses/by/4.0/
助成機関名
日本学術振興会
助成番号
19K16586
JP 20K07407